361 related articles for article (PubMed ID: 20705840)
1. AIDS/HIV. A boost for HIV vaccine design.
Burton DR; Weiss RA
Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
[No Abstract] [Full Text] [Related]
2. HIV vaccine design and the neutralizing antibody problem.
Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
[No Abstract] [Full Text] [Related]
3. AIDS/HIV. Converging on an HIV vaccine.
Korber B; Gnanakaran S
Science; 2011 Sep; 333(6049):1589-90. PubMed ID: 21921189
[No Abstract] [Full Text] [Related]
4. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
Wu X; Yang ZY; Li Y; Hogerkorp CM; Schief WR; Seaman MS; Zhou T; Schmidt SD; Wu L; Xu L; Longo NS; McKee K; O'Dell S; Louder MK; Wycuff DL; Feng Y; Nason M; Doria-Rose N; Connors M; Kwong PD; Roederer M; Wyatt RT; Nabel GJ; Mascola JR
Science; 2010 Aug; 329(5993):856-61. PubMed ID: 20616233
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA
Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595
[TBL] [Abstract][Full Text] [Related]
6. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold.
Azoitei ML; Correia BE; Ban YE; Carrico C; Kalyuzhniy O; Chen L; Schroeter A; Huang PS; McLellan JS; Kwong PD; Baker D; Strong RK; Schief WR
Science; 2011 Oct; 334(6054):373-6. PubMed ID: 22021856
[TBL] [Abstract][Full Text] [Related]
7. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
Wu X; Zhou T; Zhu J; Zhang B; Georgiev I; Wang C; Chen X; Longo NS; Louder M; McKee K; O'Dell S; Perfetto S; Schmidt SD; Shi W; Wu L; Yang Y; Yang ZY; Yang Z; Zhang Z; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Simek M; Burton DR; Koff WC; Doria-Rose NA; Connors M; ; Mullikin JC; Nabel GJ; Roederer M; Shapiro L; Kwong PD; Mascola JR
Science; 2011 Sep; 333(6049):1593-602. PubMed ID: 21835983
[TBL] [Abstract][Full Text] [Related]
8. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
9. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
[TBL] [Abstract][Full Text] [Related]
10. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
11. Population-based analysis of HIV-1 antibodies reveals structural constraints that may inform vaccine design.
Tobin SC
AIDS; 2015 Sep; 29(15):N13. PubMed ID: 26237101
[No Abstract] [Full Text] [Related]
12. AIDS research. Novel antibody response may explain HIV vaccine success.
Cohen J
Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
[No Abstract] [Full Text] [Related]
13. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
14. HIV-1-specific polyclonal and monoclonal antibodies raised with synthetic peptides: characterization and applications.
Laman JD; Schellekens MM; Paddenburg D; Tersmette M; Langedijk JP; Boersma WJ; Claassen E
Year Immunol; 1993; 7():63-8. PubMed ID: 7690509
[No Abstract] [Full Text] [Related]
15. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.
Lee HK; Scanlan CN; Huang CY; Chang AY; Calarese DA; Dwek RA; Rudd PM; Burton DR; Wilson IA; Wong CH
Angew Chem Int Ed Engl; 2004 Feb; 43(8):1000-3. PubMed ID: 14966891
[No Abstract] [Full Text] [Related]
16. B cell antigenic site mapping of HIV-1 glycoproteins.
Neurath AR
Chem Immunol; 1993; 56():34-60. PubMed ID: 8452653
[No Abstract] [Full Text] [Related]
17. Antibodies to HIV-1: aiming at the right target.
Eggink D; Melchers M; Sanders RW
Trends Microbiol; 2007 Jul; 15(7):291-4. PubMed ID: 17566740
[TBL] [Abstract][Full Text] [Related]
18. Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine.
Zhou T; Xu K
Adv Exp Med Biol; 2018; 1075():73-95. PubMed ID: 30030790
[TBL] [Abstract][Full Text] [Related]
19. HIV vaccine development--improving on natural immunity.
Johnston MI; Fauci AS
N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
[No Abstract] [Full Text] [Related]
20. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]